Helixgate

Helixgate

Uncategorized

NHS health data should be used for clinical trial recruitment, says ABPI

Published

on

""

The UK has an opportunity to enhance its global competitiveness in the delivery of industry clinical trials by harnessing NHS health data to more efficiently recruit patients, according to a new report from the ABPI. 

Following a period of decline, the number of industry clinical trials in the UK is rising again. Despite this good news, participation in these trials is falling, and is now at its lowest level since 2017/18, representing only 3.4% of individuals taking part in all UK trials. 

The ABPI’s new report, ‘Globally competitive UK-wide data-enabled clinical trials: the time is now,’ argues that the solution to rapidly recruiting more patients who are suitable for industry clinical trials is better use of NHS health data.  

A key driver of declining recruitment into industry trials is inefficient methods of identifying eligible patients. Current processes are costly and resource-intensive for an overstretched NHS, and they waste patients’ time when they are turned away because they don’t meet the trial criteria to take part. 

NHS records contain comprehensive medical information on the UK’s 69 million population. This globally unique asset could dramatically improve how patients are recruited into industry clinical trials in the UK, resulting in faster, more efficient and more inclusive processes. 

Anonymised NHS records are already being successfully used in pockets of the UK to support trial recruitment. The recent government announcement to establish a Health Data Research Service (HDRS) provides a mechanism to coordinate and streamline locating the most suitable patients for an industry clinical trial across the UK. 

A new model for health data use 

The ABPI proposal involves conducting centralised searches of anonymised NHS records within the HDRS and providing this information to NHS trial sites, which have the authority to identify patients and review their eligibility for a specific trial. This evidence-based approach matches trial eligibility criteria to information within a patient’s medical record. 

In addition to inviting more eligible patients to participate in a trial, invitations would be targeted only to those who meet the eligibility criteria based on their medical history, meaning fewer patients would be turned away at the recruitment screening stage. 

The new ABPI report sets out industry’s view of how adopting data-enabled methods would improve the predictability and accuracy of carrying out trials in the UK, by accelerating recruitment timelines and ensuring that the right patients are matched to the right studies. 

Dr Janet Valentine, ABPI Executive Director of Innovation and Research Policy, said: “Because of the benefits industry trials bring to patients and the economy, global competition to attract commercial trials is fierce. It is therefore vital that the UK acts now to secure industry investment and builds on the public’s growing enthusiasm to take part in research. 

“NHS health data offers the UK a potential leading edge on our competitors by transforming how we find and recruit patients into trials, reducing delays, costs and avoiding wasted effort. Importantly, the approach we are recommending improves efficiencies in the NHS whilst maintaining patient confidentiality. 

“Our model, which has been developed in consultation with industry, NHS leaders and service providers, aligns with the government’s priorities for research and use of health data. If we get this right, we will restore the UK’s reputation for predictable and rapid recruitment into trials, making the UK a far more attractive place for global industry research investment.” 

The post NHS health data should be used for clinical trial recruitment, says ABPI appeared first on Drug Discovery World (DDW).

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins

Published

on

You know when you are at the eye doctor getting an updated prescription, and suddenly the world snaps into sharper focus? Physicists at the University of California (UC), Berkeley, have now done something similar for electron microscopy. By introducing phase contrast into a cryo‑electron microscope, they have delivered dramatically sharper images of some of biology’s smallest and most elusive proteins.

The advance comes from a new laser phase plate (LPP), described in the paper “Laser phase plate improves structure determination of small proteins by cryo‑EM,” which was published recently in Science. Led by physicist Holger Mueller, PhD, of UC Berkeley and Lawrence Berkeley National Laboratory, the team demonstrated that a laser‑driven phase plate can overcome one of cryo‑EM’s most persistent limitations: poor contrast for small proteins.

Cryo-EM images of two proteins, apoferritin and hemoglobin, taken without and with a laser phase plate. The images are analyzed in a computer to produce detailed 3D structures of the proteins. [Holger Müller, Jessie Zhang/UC Berkeley]

Cryo‑EM has transformed structural biology over the past decade, earning a Nobel Prize in 2017 for enabling high‑resolution structures without crystallization. But despite its impact, the technique still struggles with proteins below ~70 kilodaltons—a size range that includes about 90% of the human proteome. “Because of signal-to-noise limitations, the majority of human and animal proteins are too small to be analyzed by these methods [cryo-EM and cryoelectron tomography]. The increase in signal-to-noise ratio provided by this laser phase plate is expected to overcome these important limitations.”

The new LPP begins to address that problem. The LPP uses an intense, continuous‑wave laser to shift the phase of the electron beam itself. This produces true phase contrast without dimming or destabilizing the beam. Mueller described the laser focus as “75 kilowatts focused to a few microns… That’s more powerful than what you use for welding. It has more power than a military laser. It builds up the brightest continuous laser focus ever.”

Installed in a custom Thermo Fisher Titan Krios, the LPP immediately improved the clarity and resolvability of small proteins, including hemoglobin, which sits at the lower limit of what today’s cryo‑EM instruments can handle. As the authors wrote in the abstract: “Here, we show that the laser phase plate (LPP)… enhances the resolution in single-particle reconstruction of small proteins by improving specimen-motion correction, recovery of information from the early frames, as well as particle visualization, 3D classification, and alignment.”

phase plate cover Cryo-EM
A laser (purple) is powerfully amplified by highly polished mirrors and focused on the electron beam (blue) to shift its phase and increase the cryo-EM microscope’s contrast, allowing biologists to image smaller proteins and the crowded structures inside cells. [Sayo Studio]

These improvements were achieved using standard defocus ranges and reconstruction workflows. “For the most challenging cases—small particles, bad specimens—the laser produces a very considerable advantage,” Mueller said.

 

The impact extends beyond single‑particle analysis. Cryo‑electron tomography (cryo‑ET), which assembles multiple angular views of a molecule or protein into a three-dimensional image, stands to benefit even more. “With cryo-ET, we’re looking at small, very complicated cellular material that’s incredibly crowded inside the cell,” said Bridget Carragher, PhD, founding technical director of imaging at Biohub. “It’s like a forest of trees, and you’re trying to find one leaf on one tree in there. Cryo-ET needs a dramatic step forward in contrast, so we can start to see what’s going on inside the cell. That’s what the laser phase plate promises to give us.”

Biohub is developing a dual‑laser version of the system, designed to reduce component wear and minimize aberrations. Meanwhile, Mueller’s team is pushing toward imaging proteins as small as 17 kilodaltons, a threshold that would open access to vast regions of the human proteome previously invisible to cryo‑EM.

“This technology is a step function change for biology,” said Stephani Otte, PhD, Biohub’s vice president of imaging science. “What was once invisible will become visible—and that changes everything about how we understand disease.”

“The bottom line is, if you have a large protein and a really good sample—a fresh one or one frozen without bubbles, for example—you may not need the phase plate to get a single, high-quality image. But for a small protein and a bad sample, laser-on is best,” Mueller said. “This could fill an enormous gap in our knowledge of protein structures that can’t be crystallized or are too small for today’s cryo-EM. And it will be revolutionary for cryo-ET.”

The post Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Uncategorized

STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America

Updated June 11, 2026

WASHINGTON — A pledge to “Make America Healthy Again” earned Robert F. Kennedy Jr. his job atop U.S. health agencies a year and some change ago. He’s now had the opportunity to turn his words into action, with mixed results.  

“All one needs” to prove the health secretary’s attentiveness is to “review my unprecedented list of accomplishments on a wide range of issues, all of which I drove,” Kennedy posted on X on Wednesday in response to a journalist.

Continue to STAT+ to read the full story…

Read More

Published

on

Updated June 11, 2026

WASHINGTON — A pledge to “Make America Healthy Again” earned Robert F. Kennedy Jr. his job atop U.S. health agencies a year and some change ago. He’s now had the opportunity to turn his words into action, with mixed results.  

“All one needs” to prove the health secretary’s attentiveness is to “review my unprecedented list of accomplishments on a wide range of issues, all of which I drove,” Kennedy posted on X on Wednesday in response to a journalist.

Continue to STAT+ to read the full story…

Read More

Continue Reading

Uncategorized

An obesity drug deep-dive, and peptides move mainstream

Published

on

Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow greater access to experimental peptides?

We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.

Read the rest…

Continue Reading
Advertisement

Trending